HoriuchiKKobayashiEMizunoT, et al. Hypercalcemia following discontinuation of denosumab therapy: a systematic review. Bone Rep. 2021;15:101148.
2.
AsagiriMTakayanagiH. The molecular understanding of osteoclast differentiation. Bone. 2007;40(2):251-264.
3.
MeierMEClerkxSNWinterEM, et al. Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study. J Bone Miner Res. 2021;36(9):1729-1738.
4.
KawamuraHWatanabeSITAsahinaI, et al. Efficacy and safety of denosumab treatment in a prepubertal patient with cherubism. J Pediatr Endocrinol Metab. 2020;33(7):963-966.
5.
TrejoPRauchFWardL. Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact. 2018;18(1):76-80.
6.
IrmolaTLaitinenMKParkkinenJEngellauJNevaMH. Solitary juvenile xanthogranuloma in the spine pretreated with neoadjuvant denosumab therapy followed by surgical resection in a 5-year-old child: case report and literature review. Eur Spine J. 2018;27(suppl 3):555-560.
7.
NaiduAMalmquistMPDenhamCASchowSR. Management of central giant cell granuloma with subcutaneous denosumab therapy. J Oral Maxillofac Surg. 2014;72(12):2469-2484.
8.
GrasemannCSchündelnMMHövelM, et al. Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget’s disease. J Clin Endocrinol Metab. 2013;98(8):3121-3126.
9.
BoyceAMChongWHYaoJ, et al. Denosumab treatment for fibrous dysplasia. J Bone Miner Res. 2012;27(7):1462-1470.
10.
Del SindacoGBerlangaPBrugièresL, et al. Mineral and bone consequences of high dose denosumab therapy to treat an aneurysmal bone cyst, a child case report. Front Endocrinol (Lausanne). 2021;12:698963.
11.
FerrieroKShahBYanY, et al. Case report: safety and efficacy of denosumab in four children with Noonan syndrome with multiple giant cell lesions of the jaw. Front Pediatr. 2020;8:515.
12.
AnastasilakisADMakrasPDoulgerakiAPolyzosSAGuarnieriVPapapoulosSE. Denosumab for the treatment of primary pediatric osteoporosis. Osteoporos Int. 2021;32(11):2377-2381.
13.
VandernietJAWallCLMullinsA, et al. Denosumab for central giant cell granuloma in an Australian tertiary paediatric centre. Bone. 2022;159:116395.
14.
RhouYJJWangCJNguyenM, et al. Clinical and radiologic response of central giant cell granuloma to denosumab: a 6-year prospective observational study. Calcif Tissue Int. 2022;110(4):464-474.
15.
de LangeJvan den AkkerHPvan den BergH. Central giant cell granuloma of the jaw: a review of the literature with emphasis on therapy options. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104(5):603-615.
16.
ChoeMSmithVOkcuMF, et al. Treatment of central giant cell granuloma in children with denosumab. Pediatr Blood Cancer. 2021;68(3):e28778.
17.
MarizBALAMiglioratiCAAlvesFA, et al. Successful denosumab treatment for central giant cell granuloma in a 9-year-old child. Spec Care Dentist. 2021;41(4):519-525.
18.
RauxSBouhamamaAGasparN, et al. Denosumab for treating aneurysmal bone cysts in children. Orthop Traumatol Surg Res. 2019;105(6):1181-1185.
19.
DürrHRGrahneisFBaur-MelnykA, et al. Aneurysmal bone cyst: results of an off label treatment with denosumab. BMC Musculoskelet Disord. 2019;20(1):456.
20.
KurucuNAkyuzCErgenFB, et al. Denosumab treatment in aneurysmal bone cyst: evaluation of nine cases. Pediatr Blood Cancer. 2018;65(4):e26926.
21.
SetsuNKobayashiEAsanoN, et al. Severe hypercalcemia following denosumab treatment in a juvenile patient. J Bone Miner Metab. 2016;34(1):118-122.
22.
DeodatiAFintiniDLevtchenkoE, et al. Mechanisms of acute hypercalcemia in pediatric patients following the interruption of denosumab. J Endocrinol Invest. 2022;45(1):159-166.
23.
SimmPJBigginAZacharinMR, et al. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. J Paediatr Child Health. 2018;54(3):223-233.
24.
Koldkjær SøllingASHarsløfTKaalARejnmarkLLangdahlB. Hypercalcemia after discontinuation of long-term denosumab treatment. Osteoporos Int. 2016;27(7):2383-2386.
25.
GossaiNHilgersMVPolgreenLEGreengardEG. Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone. Pediatr Blood Cancer. 2015;62(6):1078-1080.
26.
RabornLNBurkeABEbbDHCollinsMTKabanLBBoyceAM. Denosumab for craniofacial fibrous dysplasia: duration of efficacy and post-treatment effects. Osteoporos Int. 2021;32(9):1889-1893.
27.
HarcusMAldridgeSAbuduA, et al. The efficacy of denosumab in the management of a tibial paediatric aneurysmal bone cyst compromised by rebound hypercalcaemia. Case Rep Pediatr. 2020;2020:8854441.
28.
Upfill-BrownABukataSBernthalNM, et al. Use of denosumab in children with osteoclast bone dysplasias: report of three cases. JBMR Plus. 2019;3(10):e10210.
29.
UdaySGastonCLRogersL, et al. Osteonecrosis of the jaw and rebound hypercalcemia in young people treated with denosumab for giant cell tumor of bone. J Clin Endocrinol Metab. 2018;103(2):596-603.
30.
SydlikCDürrHRPozzaSBWeißenbacherCRoebJSchmidtH. Hypercalcaemia after treatment with denosumab in children: bisphosphonates as an option for therapy and prevention?World J Pediatr. 2020;16(5):520-527.
31.
Hoyer-KuhnHRehbergMNetzerC, et al. Individualized treatment with denosumab in children with osteogenesis imperfecta—follow up of a trial cohort. Orphanet J Rare Dis. 2019;14(1):219.
32.
BoyceAM. Denosumab: an emerging therapy in pediatric bone disorders. Curr Osteoporos Rep. 2017;15(4):283-292.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
